Compare NNY & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NNY | PYXS |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.3M | 141.3M |
| IPO Year | N/A | 2021 |
| Metric | NNY | PYXS |
|---|---|---|
| Price | $7.85 | $3.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 53.8K | ★ 848.7K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 4.04% | N/A |
| EPS Growth | N/A | ★ 3.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7,043.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.75 | $1.03 |
| 52 Week High | $8.94 | $5.55 |
| Indicator | NNY | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 25.47 | 52.01 |
| Support Level | N/A | $2.95 |
| Resistance Level | $8.81 | $3.45 |
| Average True Range (ATR) | 0.08 | 0.32 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 15.89 | 29.86 |
Nuveen New York Municipal Value Fund Inc. is a diversified closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.